{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:03Z","timestamp":1792661223493,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.neuroscience.2011.01.033","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T09:24:51Z","timestamp":1296120291000},"page":"208-222","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments"],"prefix":"10.1016","volume":"179","author":[{"given":"S.G.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.H.","family":"Al-Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ancharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2011.01.033_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0003023","article-title":"Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain","volume":"3","author":"Adekar","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/jpet.108.136242","article-title":"The role of systemic handling in the pathophysiologic actions of botulinum toxin","volume":"326","author":"Al-Saleem","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib4","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","article-title":"Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment","volume":"45","author":"Atassi","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1615\/CritRevImmunol.v27.i4.30","article-title":"Molecular bases of protective immune responses against botulinum neurotoxin A\u2014how antitoxin antibodies block its action","volume":"27","author":"Atassi","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.5858\/2004-128-653-CBATCL","article-title":"Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin","volume":"128","author":"Caya","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib7","series-title":"From neuroscience to neurology","first-page":"125","article-title":"Botulinum toxins: transformation of a toxin into a treatment","author":"Comella","year":"2005"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib8","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1097\/00002508-200211001-00004","article-title":"Considering the immune response to botulinum toxin","volume":"18","author":"Critchfield","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0041-0101(84)90085-0","article-title":"Purification and amino acid composition of type A botulinum neurotoxin","volume":"22","author":"DasGupta","year":"1984","journal-title":"Toxicon"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","article-title":"Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy","volume":"48","author":"Dressler","year":"2002","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib11","doi-asserted-by":"crossref","first-page":"24777","DOI":"10.1074\/jbc.M703446200","article-title":"A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms","volume":"282","author":"Hasegawa","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199104253241707","article-title":"Therapeutic uses of botulinum toxin","volume":"324","author":"Jankovic","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.neuroscience.2005.12.029","article-title":"Recovery from botulinum neurotoxin poisoning in vivo","volume":"139","author":"Keller","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib15","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1242\/jcs.112.16.2715","article-title":"Functional characterisation of tetanus and botulinum neurotoxins binding domains","volume":"112","author":"Lalli","year":"1999","journal-title":"J Cell Sci"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10930-008-9151-2","article-title":"Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis","volume":"27","author":"Lietzow","year":"2008","journal-title":"Protein J"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"Muller","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib18","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1099\/mic.0.28323-0","article-title":"Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes","volume":"151","author":"Mutoh","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.toxicon.2009.03.020","article-title":"Dysport: pharmacological properties and factors that influence toxin action","volume":"54","author":"Pickett","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1292\/jvms.71.447","article-title":"Analysis of the properties of neutralizing monoclonal antibodies against the hemagglutinating encephalomyelitis virus and inhibition of HEV infection by specific MAb","volume":"71","author":"Raihana","year":"2009","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib21","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/IAI.01893-06","article-title":"A trivalent vaccine against botulinum toxin (serotypes A, B, and E) that can be administered by the mucosal route","volume":"75","author":"Ravichandran","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1124\/jpet.106.104661","article-title":"An initial assessment of the systemic pharmacokinetics of botulinum toxin","volume":"318","author":"Ravichandran","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1353\/pbm.1997.0032","article-title":"Botulinum toxin: the story of its development for the treatment of human disease","volume":"40","author":"Schantz","year":"1997","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-129-3-199808010-00011","article-title":"Botulism in the United States: a clinical and epidemiologic review","volume":"129","author":"Shapiro","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib25","series-title":"Vaccines for biodefense and emerging and neglected diseases","first-page":"891","article-title":"Botulinum toxin","author":"Simpson","year":"2009"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0022-3565(25)12758-4","article-title":"Use of monoclonal antibodies as probes for the structure and biological activity of botulinum neurotoxin","volume":"255","author":"Simpson","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10930-005-7839-0","article-title":"The role of exoproteases in governing intraneuronal metabolism of botulinum toxin","volume":"24","author":"Simpson","year":"2005","journal-title":"Protein J"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0076-6879(88)65015-4","article-title":"Isolation and characterization of the botulinum neurotoxins","volume":"165","author":"Simpson","year":"1988","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib29","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3201\/eid1009.030745","article-title":"Foodborne botulism in the United States, 1990\u20132000","volume":"10","author":"Sobel","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1099\/mic.0.27801-0","article-title":"Characterization of the interaction between subunits of the botulinum toxin complex produced by serotype D through tryptic susceptibility of the isolated components and complex forms","volume":"151","author":"Suzuki","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib31","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.vaccine.2009.02.051","article-title":"Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin","volume":"27","author":"Takahashi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.neuroscience.2011.01.033_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10930-006-9041-4","article-title":"Cloning, expression, purification, and characterization of biologically active recombinant hemagglutinin-33 type A botulinum neurotoxin associated protein","volume":"26","author":"Zhou","year":"2007","journal-title":"Protein J"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645221100056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645221100056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:38:03Z","timestamp":1740893883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030645221100056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":32,"alternative-id":["S030645221100056X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2011.01.033","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}